Delivery of biologics in cardiovascular regenerative medicine

J. Bartunek, W. Sherman, M. Vanderheyden, F. Fernandez-Aviles, W. Wijns, A. Terzic

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

Stem cell-based cardiovascular regenerative medicine offers the next frontier of therapy through delivery of progenitor cells to achieve structural and functional repair of the myocardium. Initial clinical experience indicates that such therapy is feasible and safe, yet structural and functional benefits remain rather modest. A common pitfall in all studies is the very low rate of cell retention by the recipient myocardial tissue. This limitation warrants lead optimization so as to improve the outcome of stem cell delivery.

Original languageEnglish (US)
Pages (from-to)548-552
Number of pages5
JournalClinical pharmacology and therapeutics
Volume85
Issue number5
DOIs
StatePublished - May 1 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Delivery of biologics in cardiovascular regenerative medicine'. Together they form a unique fingerprint.

  • Cite this

    Bartunek, J., Sherman, W., Vanderheyden, M., Fernandez-Aviles, F., Wijns, W., & Terzic, A. (2009). Delivery of biologics in cardiovascular regenerative medicine. Clinical pharmacology and therapeutics, 85(5), 548-552. https://doi.org/10.1038/clpt.2008.295